amenamevir
Small moleculeexperimental
Clinical trial activity
13 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT02852876)
Timeline
Indications
Mechanism of action
- Human herpesvirus 3INHIBITOR
Human herpesvirus 3 inhibitor
- Helicase primate complexINHIBITOR
Helicase primate complex inhibitor
Amenamevir inhibited DNA replication of VZV, HSV-1, and HSV-2 at ≥0.03 μmol/L, but not HCMV.
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cccc(C)c1N(CC(=O)Nc1ccc(-c2ncon2)cc1)C(=O)C1CCS(=O)(=O)CC1- Mol. weight
- 482.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297592 ↗
Also known as
- amenamevir
- asp2151
- asp2151
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02403635 | Phase 1 | Apr 1, 2015 | Maruho Co., Ltd. |
| NCT02369172 | Phase 1 | Feb 1, 2015 | Maruho Co., Ltd. |
| NCT02321748 | Phase 1 | Dec 1, 2014 | Maruho Co., Ltd. |
| NCT02280421 | Phase 1 | Oct 1, 2014 | Maruho Co., Ltd. |
| NCT02223351 | Phase 1 | Sep 1, 2014 | Maruho Co., Ltd. |
| NCT02209324 | Phase 3 | Nov 1, 2013 | Maruho Co., Ltd. |
| NCT01959295 | Phase 3 | Aug 1, 2013 | Maruho Co., Ltd. |
| NCT01959841 | Phase 3 | Aug 1, 2013 | Maruho Co., Ltd. |
| NCT00870441 | Phase 1 | Mar 1, 2009 | Astellas |
| NCT00487682 | Phase 2 | Aug 1, 2007 | Astellas |
| NCT00486200 | Phase 2 | Jun 1, 2007 | Astellas |
| NCT02796118 | Phase 1 | Jul 1, 2006 | Astellas |
| NCT02852876 | Phase 1 | Sep 1, 2005 | Astellas |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Maruho Co., Ltd. | For profit | 8 | 8 | 2 | 2013 |
| Astellas | For profit | 5 | 5 | 2 | 2005 |
2 organizations
Page 1 / 1